What does this mean practically for research in Europe, and what are the best practices for implementation?
27 August, 2013 in Brussels.
- Best practices in the use of clinical trial data
- Building a European data sharing health infrastructure
- Balancing public health and commercial confidentiality
|Event programme (Agenda, Speakers)|
The question of what information – if any – should be defined as commercially confidential remains in dispute and this could hinder progress in creating a balanced, practical and trusted system for handling requests for data.
Research by the ABPI indicates current statistics on the state of play in transparency are not accurate. A toolkit will guide members in complying with disclosure requirements and generate more reliable information on compliance.
Providing controlled access to identified patient-level information is an essential element of realising the full potential of clinical data stores.
It’s time for rapprochement between academic campaigners and pharma companies over clinical trials data transparency
The current polarised debate is not helpful to anyone, least of all patients, says Alastair Kent of Genetic Alliance UK.
European pharma industry stages workshop to consider practical issues involved in clinical trials data transparency
After setting out principles under which the industry is prepared to open up clinical study reports, the European Federation of Pharmaceutical Industries and Associations (EFPIA) is trying to reach a consensus with campaigners and regulators on how they should be applied in practice.
|Hans Georg-Eichler Senior Medical Officer, European Medicine’s Agency||Ben Goldacre Wellcome Research Fellow in Epidemiology, London School of Hygiene and Tropical Medicine||Richard Bergstrom Director General, EFPIA||Susanna Palkonen Vice President, European Patients’ Forum|
The event will take place at Vlerick Business School, Manhattan Centre, Place Rogier, 21 Avenue du Boulevard in Brussels.